Clinical trial
Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of…
NCT00221845 · Heidelberg University, Other · Completed
Key facts
| NCT number | NCT00221845 |
|---|---|
| Title | Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients |
| Official title | Molecular Mechanisms of Disease Progression and Renoprotective Pharmacotherapy in Children With Chronic Renal Failure |
| Acronym | ESCAPE |
| Lead sponsor | Heidelberg University, Other |
| Collaborators | European Commission Boehringer Ingelheim Industry Baxter Healthcare Corporation Aventis Pharmaceuticals |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Children, Chronic Renal Failure, Hypertension, Acquired Kidney Disease, Congenital Kidney Disease |
| Intervention type | Drug |
| Interventions | ACE Inhibition, Intensified Blood Pressure Control, Add-on Angiotensin Receptor Blockade |
| Enrollment | 400 |
| Start date | Jan 1, 1998 |
| Primary completion | Jul 1, 2007 |
| Completion | Jan 1, 2010 |
| First posted | Sep 22, 2005 |
| Last update posted | Jan 12, 2010 |
| Countries | Czechia, France, Germany, Hungary, Italy, Lithuania, Poland, Portugal, Serbia, Sweden, Switzerland, Turkey (Türkiye) |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: